Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine

Related Experiment Video

Updated: Mar 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Li-Mei Poon1, Yok-Lam Kwong2

  • 1Department of Hematology-Oncology, National University Cancer Institute of Singapore, Singapore, Singapore.

Annals of Hematology
|March 3, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Experiment Videos

Last Updated: Mar 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Multimodal spatial profiling reveals distinct myeloid-defined ENKTL subgroups and tumor-myeloid cooperativity within prognostic inflammatory niche.

Leukemia·2026

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026

Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions.

Cancers·2026

Epidemiology of mature T-cell and NK-cell neoplasms: east and west.

The Lancet regional health. Western Pacific·2025

Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas.

The Lancet. Haematology·2025

A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia.

Blood cancer journal·2025

Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.

Annals of hematology·2026

Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.

Annals of hematology·2026

Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group.

Annals of hematology·2026

Non-pharmacological interventions as adjuncts to iron chelation therapy in sickle cell disease on chronic transfusion: a scoping review with evidence gap mapping.

Annals of hematology·2026

Cyanosis and extensive erythroid dysplasia in a young adult with hemoglobin M-Hyde Park (Akita).

Annals of hematology·2026

Genetic and clinical phenotype analysis of a case of high-molecular-weight kininogen deficiency caused by a frameshift mutation c.628_629delAA in the KNG1 gene.

Annals of hematology·2026

Targeting MALT1 in B-cell Lymphomas.

Blood cancer discovery·2026

From Dysfunction to Differentiation: A New Paradigm of T Cell Exhaustion.

Acta naturae·2026

Additional B-Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real-World Retrospective Observational Single-Center Cohort Study.

MedComm·2026

Targeting BIGH3 in selected solid tumors through a pH-Dependent antibody engineering strategy.

Biochemistry and biophysics reports·2026

Correction: Solving the mystery of persistent isolated aspartate aminotransferase elevation: Macro-AST as a decisive diagnostic consideration.

Frontiers in cellular and infection microbiology·2026

Calcineurin Inhibitor-Free, mTOR-Based Immunosuppression in Chimeric Antigen Receptor T-Cell Therapy for Post-Transplant Lymphoproliferative Disorder.

EJHaem·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us